Legend Biotech Corporation (ADR)
General ticker "LEGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.7B (TTM average)
Legend Biotech Corporation (ADR) follows the US Stock Market performance with the rate: 2.7%.
Estimated limits based on current volatility of 3.6%: low 18.24$, high 19.58$
Factors to consider:
- Total employees count: 2900 (+11.5%) as of 2025
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [14.68$, 33.51$]
- 2026-12-31 to 2027-12-31 estimated range: [15.58$, 34.46$]
Financial Metrics affecting the LEGN estimates:
- Positive: with PPE of -37.2 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: Inventory ratio change, % of 5.58 > 4.02
- Negative: negative Industry operating income (median)
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: 49.86 < Shareholder equity ratio, % of 57.80 <= 58.56
- Positive: -13.52 < Operating profit margin, % of -11.71
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Negative: 0.33 < Interest expense per share per price, % of 0.52
- Negative: negative Industry operating cash flow (median)
Short-term LEGN quotes
Long-term LEGN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $285.14MM | $627.24MM | $1,028.90MM |
| Operating Expenses | $724.63MM | $930.48MM | $1,165.40MM |
| Operating Income | $-439.49MM | $-303.24MM | $-136.50MM |
| Non-Operating Income | $-80.63MM | $145.11MM | $-146.10MM |
| Interest Expense | $21.79MM | $21.61MM | $21.40MM |
| R&D Expense | $382.22MM | $413.54MM | $414.70MM |
| Income(Loss) | $-520.12MM | $-158.13MM | $-282.60MM |
| Taxes | $0.00MM | $0.00MM | $14.20MM |
| Net Income(Loss)* | $-518.25MM | $-177.03MM | $-296.02MM |
| Stockholders Equity | $1,251.37MM | $1,040.55MM | $1,002.10MM |
| Inventory | $19.43MM | $23.90MM | $32.00MM |
| Assets | $1,848.61MM | $1,670.15MM | $1,733.70MM |
| Operating Cash Flow | $-393.28MM | $-144.03MM | $-100.47MM |
| Capital expenditure | $22.72MM | $14.11MM | $67.58MM |
| Investing Cash Flow | $92.79MM | $-850.54MM | $711.48MM |
| Financing Cash Flow | $791.49MM | $5.70MM | $-0.30MM |
| Earnings Per Share** | $-2.94 | $-0.97 | $-1.61 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.